NCT06479135 · Interventional trial
Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib
Overall registry status Recruiting
Phase 3
Conditions MF, Myelofibrosis, Post-ET Myelofibrosis, Post-PV MF, Primary Myelofibrosis
Delaware Valley sites
- Abramson Cancer Center of the University of Pennsylvania · Philadelphia, PA · Philadelphia County · Recruiting
First posted
Registry updated
Added to the directory